ALGS compared with CRMD: revenue, margins and what each company keeps, and the suppliers and customers both name

ALGSAligos Therapeutics, Inc.

Mkt capRevenueRevenue

CRMDCorMedix Inc.

Mkt capRevenueRevenue

Compare

ALGSAligos Therapeutics, Inc.

CRMDCorMedix Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALGS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+16.24%—

CRMD

1 of 3at or beyond implied

Reportimpliedrealized× implied

Nov 2 '26—▼−5.36%—

Q2 FY26±13.6%▲+14.65%×1.08

= impliedALGS realized, solidCRMD realized, hatchedOne scale, both sides: full bar = 24%× = |realized| ÷ impliedSource: market data

May 14 '26

±13.7%

▲+5.73%

×0.42

Q1 FY26±23.0%▼−11.52%×0.50

ALGSAligos Therapeutics, Inc.

4.69· pre 4.60· delayed

Mkt cap$59.9MRevenue$28MQ2 FY26Revenue$2MFY25

CRMDCorMedix Inc.

5.40· pre 5.40· delayed

Pre-marketNov 3 '26delayed

Mkt cap$526.7MRevenue$102MQ2 FY26Revenue$298MFY25

Compare

Pre-marketNov 3 '26delayed

ALGSAligos Therapeutics, Inc.

CRMDCorMedix Inc.

4.69pre 4.60delayed

Price

5.40pre 5.40delayed

$59.9M

Mkt cap

$526.7M

Q2 FY26$28M

Revenue

$102MQ2 FY26

FY25$2M

Revenue

$298MFY25

ALGS4.69vsCRMD5.40Pre-marketNov 3 '26delayed